Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Soft cannabinoid analogues as potential anti-glaucoma agents.

A Buchwald1, H Derendorf, F Ji

  • 1Center for Drug Discovery, College of Pharmacy, University of Florida, Gainesville, Florida, USA. abuchwald@kospharm.com

Die Pharmazie
|March 7, 2002
PubMed
Summary

New cannabinoid derivatives lower intraocular pressure (IOP) effectively for glaucoma treatment. These soft drugs target local effects, avoiding systemic side effects and offering a safer therapeutic option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Multifrequency attenuation patterns in age-related hearing loss: a longitudinal analysis using spline mixed-effects models].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2026
Same author

[Perioperative digital surveillance with a multiparameter vital signs monitoring system in a gastric cancer patient with diabetes].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery·2025
Same author

[Relationship between <i>GST</i> gene polymorphism and susceptibility to occupational noise induced hearing loss].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases·2025
Same author

[Investigation and influencing factors of hearing loss among workers in a gas production plant].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases·2025
Same author

[Innovative research directions for hearing disorders in the aged].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2024
Same author

CircNRCAM up-regulates NRCAM to promote papillary thyroid carcinoma progression.

Journal of endocrinological investigation·2024

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Cannabinoids can reduce intraocular pressure (IOP), a key factor in glaucoma.
  • Current cannabinoid use for glaucoma is limited by significant systemic side effects.
  • A retrometabolic/soft drug approach was employed to design novel cannabinoid derivatives.

Purpose of the Study:

  • To design and synthesize novel cannabinoid derivatives with a local effect on IOP.
  • To minimize or eliminate systemic side effects associated with cannabinoid use.
  • To evaluate the efficacy and safety of these soft drug analogues for glaucoma management.

Main Methods:

  • Synthesis of lead compounds and soft analogues using Pechmann condensation.
  • Evaluation of intraocular pressure (IOP) lowering effects of synthesized compounds.

Related Experiment Videos

  • Pharmacokinetic/pharmacodynamic (PK/PD) modeling to describe experimental data.

    • Main Results:

    • All successfully synthesized compounds demonstrated an IOP-lowering effect.
    • The common metabolite of the soft analogues was found to be inactive.
    • Soft analogue 8 showed prolonged topical effect but no systemic activity, with its metabolite being inactive.
    • PK/PD modeling successfully described preliminary intravenous experimental data.

    Conclusions:

    • Designed soft cannabinoid analogues are effective for topical glaucoma control.
    • These analogues minimize systemic side effects, offering a safer alternative.
    • The retrometabolic/soft drug strategy is promising for developing novel glaucoma therapeutics.